Physician profile
Marty Allen
NPI 1639217391
$39,708.96
in general payments reported to CMS, 2019-2025
15 companies · $3,907 in 2025
The $3,907 reported for 2025 was more than what 89% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,159 · 2020: $442 · 2021: $472 · 2022: $6,645 · 2023: $9,683 · 2024: $11K · 2025: $3,907.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Travel and Lodging: $3,973 · Food and Beverage: $2,855 · Education: $32.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,130.00 |
| Travel and Lodging | $3,972.60 |
| Food and Beverage | $2,855.30 |
| Education | $32.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $36,201.09 | 2019-2025 | Cresemba |
| Gilead Sciences, INC. | $1,316.09 | 2019-2025 | Veklury, Yeztugo |
| Viiv Healthcare Company | $564.80 | 2019-2025 | Dovato, Apretude, Cabenuva |
| Shionogi INC | $504.34 | 2021-2025 | Fetroja |
| Romark Laboratories, Lc | $380.08 | 2019-2020 | |
| La Jolla Pharmaceutical Company | $204.95 | 2022-2025 | Zevtera |
| Merck Sharp & Dohme LLC | $135.77 | 2019-2022 | |
| Allergan, INC. | $112.91 | 2020 | |
| Janssen Biotech, INC. | $94.16 | 2021-2022 | |
| Insmed, INC. | $53.78 | 2020-2025 | Arikayce |
| Cumberland Pharmaceuticals, INC. | $51.54 | 2024 | Vibativ |
| Abbvie INC. | $50.94 | 2021-2025 | Dalvance |
| Theratechnologies INC. | $13.69 | 2019 | |
| Mylan Specialty L.P. | $12.87 | 2019 | |
| Melinta Therapeutics, LLC | $11.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marty Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.